{
    "clinical_study": {
        "@rank": "82173", 
        "arm_group": [
            {
                "arm_group_label": "Subjects treated with BMS-986094/INX-08189", 
                "description": "Subjects who participated in a clinical trial in which at least 1 dose of BMS-986094/INX-08189 was administered"
            }, 
            {
                "arm_group_label": "Subjects treated with Placebo matching BMS-986094/INX-08189", 
                "description": "Subjects who participated in a clinical trial in which at least 1 dose of Placebo matching BMS-986094/INX-08189 was administered"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the rate of kidney or heart impairment, if any, in\n      subjects who received BMS-986094 (INX-08189) in Phase 1 clinical trials"
        }, 
        "brief_title": "A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Healthy", 
            "Hepatitis C"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy and hepatitis C virus (HCV)-infected subjects who participated in prior Phase\n             1 trial with BMS-986094/INX-08189 and:\n\n               1. Received at least 1 dose of INX-08189 or\n\n               2. Received placebo in studies for HCV-infected subjects (INH-189-002 or\n                  INH-189-006)\n\n          -  Age 18 or older\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects who participated in prior trial with BMS-986094/INX-08189 and received at least 1\n        dose of INX-08189 or placebo in trials INH-189-002 or INH-189-006"
            }
        }, 
        "enrollment": {
            "#text": "204", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732848", 
            "org_study_id": "AI472-013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Subjects treated with BMS-986094/INX-08189", 
                "intervention_name": "BMS-986094/INX-08189", 
                "intervention_type": "Drug", 
                "other_name": "Observational study - No Intervention subjects were previously treated with BMS-986094/INX-08189"
            }, 
            {
                "arm_group_label": "Subjects treated with Placebo matching BMS-986094/INX-08189", 
                "intervention_name": "Placebo matching BMS-986094/INX-08189", 
                "intervention_type": "Drug", 
                "other_name": "Observational study - No Intervention subjects were previously treated with Placebo matching BMS-986094/INX-08189"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Volunteers", 
        "lastchanged_date": "August 8, 2013", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Lydie L Hazan, Site 0002", 
                    "phone": "310-289-8242"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90036"
                    }, 
                    "name": "Axis Clinical Trials"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mark A Matson, Site 0003", 
                    "phone": "651-641-2900"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Paul", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55114"
                    }, 
                    "name": "Prism Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "William Smith, Site 0005", 
                    "phone": "865-544-9100"
                }, 
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "New Orleans Center For Clinical Research - Knoxville"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eric Lawitz, Site 0004", 
                    "phone": "210-253-3426"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }, 
                    "name": "Alamo Medical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0001"
                }, 
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "00927"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Puerto Rico"
            ]
        }, 
        "number_of_groups": "2", 
        "official_title": "A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "For participation information at a USA site use a phone number below. For Site information outside USA please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of email MUST contain NCT# & Site#. Only trial site that are recruiting have contact information at this time"
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Rate of renal impairment among subjects exposed to BMS-986094 in the Phase 1 program that meet the predefined criteria for impaired renal function and require referral to a nephrologist", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 90"
            }, 
            {
                "measure": "Rate of cardiac impairment among subjects exposed to BMS-986094 in the Phase 1 program that meet the predefined criteria for impaired cardiac function and require referral to a cardiologist", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 90"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732848"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Changes in the electrocardiographic parameters observed in association with prior exposure to single and multiple oral doses of BMS-986094 compared to pre-exposure electrocardiograms (ECGs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline (pre-dose Day 1 ECG from parent study) and By Day 30"
            }, 
            {
                "measure": "Abnormalities in cardiac ejection fraction (EF) as determined by trans-thoracic echocardiogram that may be associated with prior exposure to single or multiple oral doses of BMS-986094", 
                "safety_issue": "Yes", 
                "time_frame": "By Day 90"
            }, 
            {
                "measure": "Abnormalities in B-type-natriuretic peptide (BNP) levels that may be associated with prior exposure to single or multiple oral doses of BMS-986094", 
                "safety_issue": "Yes", 
                "time_frame": "By Day 30"
            }, 
            {
                "measure": "Changes in serum creatinine levels compared to pre-exposure levels that may be associated with prior exposure to single or multiple oral doses of BMS-986094", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline (Day 1 from parent study) and By Day 14"
            }, 
            {
                "measure": "Abnormalities in urinary albumin excretion that may be associated with prior exposure to single or multiple oral doses of BMS-986094", 
                "safety_issue": "Yes", 
                "time_frame": "By Day 7"
            }, 
            {
                "measure": "Presence of signs, symptoms or medical history suggestive of heart failure or renal failure that may have been observed since last exposure to BMS-986094", 
                "safety_issue": "Yes", 
                "time_frame": "By Day 90"
            }, 
            {
                "measure": "Abnormalities in creatine phosphokinase (CPK) and creatine phosphokinase-metabolic (CPK-MB) levels that may be associated with prior exposure to single or multiple doses of BMS-986094", 
                "safety_issue": "Yes", 
                "time_frame": "By Day 30"
            }, 
            {
                "measure": "Abnormalities in troponin levels that may be associated with prior exposure to single or multiple doses of BMS-986094", 
                "safety_issue": "Yes", 
                "time_frame": "By Day 30"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}